October 20, 2023 – Pembrolizumab increases response in resectable gastric, gastroesophageal junction cancers

MADRID — Pembrolizumab with chemotherapy before and after surgery increased pathologic complete response among patients with locally advanced gastric or gastroesophageal junction cancer, according to findings presented at ESMO Congress.

However, the approach did not confer a statistically significant benefit in EFS or OS, results of the randomized phase 3 KEYNOTE-585 study showed.

Read more>